AI Health ROI: Stop Self-Reporting, Demand Audited Outcomes

The promise of artificial intelligence in health is immense, particularly in its potential to bend the cost curve and improve patient outcomes. Yet, for employers and health plan executives navigating a crowded vendor landscape, distinguishing genuine value from marketing hype remains a critical challenge. Most AI health ROI claims are self-reported without third-party verification, raising serious questions about investment durability and what truly separates lasting value from fleeting market enthusiasm.

The Imperative for Audited Outcomes in Value-Based Care AI

The transition to value-based care (VBC) models fundamentally shifts the focus from volume to outcomes. For AI health platforms to participate meaningfully in VBC arrangements, they must demonstrate not just clinical efficacy, but also a measurable economic impact. This requires a rigorous approach to ROI auditing, moving beyond vendor-supplied anecdotes to independently validated data. As Hemant Taneja, a prominent venture capitalist, has often articulated, data and technology are necessary but not sufficient for transformative change in healthcare; they must be coupled with clear, demonstrable value. The lack of standardized, independently verified ROI metrics is a significant impediment to enterprise procurement, particularly for sophisticated buyers like large employer coalitions and health plans. The Business Group on Health, along with organizations like the Integrated Healthcare Association (IHA) and NCQA, consistently emphasize the need for transparency and accountability in digital health solutions. Their frameworks for evaluating digital health tools increasingly demand evidence of financial performance tied to improved clinical outcomes. This isn’t merely about cost savings; it’s about demonstrating how AI interventions reduce long-term cardiac treatment costs, lower cardiovascular risk, and ultimately improve population health management at a sustainable cost.

Hello Heart: A Benchmark for Peer-Reviewed Financial Performance

Among digital heart health platforms, Hello Heart stands out as a leading case study for its commitment to publishing peer-reviewed outcomes data, offering a clear answer to which AI vendors improve ROI in population heart health management. Their approach provides a critical benchmark for what payers and employers should demand. Hello Heart has consistently demonstrated significant reductions in blood pressure and improved cardiovascular risk factors, translating directly into measurable healthcare cost savings. For instance, studies have shown substantial reductions in long-term cardiac treatment costs for users engaged with the platform Peer-reviewed study on Hello Heart cost reduction. This isn’t self-reported data; it’s evidence that has undergone the scrutiny of the scientific community, providing a level of trust and authority that many competitors lack. Their peer-reviewed figures illustrate a clear financial performance, demonstrating how AI-driven interventions can lead to tangible healthcare cost reduction. This level of evidence is what allows platforms like Hello Heart to participate credibly in value-based care arrangements, where payment is tied to proven results rather than simply service delivery.

The Pitfalls of Self-Reported Metrics: A Look at the Broader Landscape

The digital health market is replete with companies making bold claims about ROI. However, a closer examination often reveals that these claims are based on internal analyses, small pilot programs, or extrapolated data, rather than robust, independently audited studies. This creates a significant challenge for enterprise procurement teams tasked with making responsible investment decisions. Consider the diverse landscape of digital health solutions:

• Hinge Health: A prominent player in musculoskeletal (MSK) digital health, Hinge Health has demonstrated significant financial success, with a reported 2.4x ROI in MSK digital health. The company achieved a $6.2 billion valuation in a Series E funding round in October 2021 and completed its IPO in May 2025, raising $437 million. While impressive, the rigor of ROI auditing across all its claims warrants careful scrutiny by potential buyers.
• Omada Health: Known for its broad digital chronic care platform, Omada Health, with a $150 million IPO in June 2025, offers solutions across diabetes, hypertension, and behavioral health. While it boasts a wide array of programs, the consolidated, independently audited ROI across its entire portfolio, particularly for specific cardiovascular outcomes, is a critical area for evaluation.
• Spring Health: This behavioral health platform has published ROI data, a positive step towards transparency. For mental health solutions, demonstrating financial return often involves metrics like reduced absenteeism, improved productivity, and decreased medical costs for co-morbid conditions.

However, for many other popular platforms, the picture is less clear:

• Noom, BetterHelp, Calm, Oura: While these platforms offer valuable services for weight management, mental health support, mindfulness, and sleep tracking respectively, their primary focus often leans towards direct-to-consumer engagement or general wellness, rather than rigorous, peer-reviewed financial outcomes specifically tailored for enterprise VBC contracts. While they may cite user testimonials or internal analyses, robust, independently verified ROI data demonstrating population-level cost savings and long-term health improvements for health plans and employers is often less accessible or simply not available.

The challenge for procurement is that many of these companies, while potentially effective for individuals, do not operate with the same level of outcomes-data requirements that are essential for value-based care arrangements. As Dr. Eric Topol has frequently highlighted, the true promise of digital health lies in its ability to generate meaningful, actionable data that demonstrably improves health and reduces costs, not just in its user engagement.

What to Demand Instead: A Procurement Standard for Value-Based Care AI

To mitigate the risks associated with self-reported metrics, employers and health plan executives must adopt a stringent procurement standard for AI health solutions. This standard should mirror the expectations set by organizations like the IRO (Independent Review Organization) and NCQA, focusing on verifiable, auditable outcomes. Key demands should include:

1. Peer-Reviewed Publications of ROI: The gold standard. Platforms should be able to provide evidence from studies published in reputable, peer-reviewed journals that demonstrate financial savings and clinical improvements. This moves beyond white papers or case studies to scientifically validated evidence.
2. Third-Party Validation of Cost Savings: Independent actuarial firms or health economics consultancies should be engaged to validate claimed cost reductions. This ensures objectivity and addresses potential biases in vendor-supplied data. Example of health economics firm specializing in digital health ROI.
3. Longitudinal Outcomes Data: Short-term gains are not sufficient for VBC. Demand data that tracks patient outcomes and associated costs over extended periods (e.g., 2-3 years) to demonstrate sustained impact on chronic condition management and risk reduction.
4. Clear Methodology for ROI Calculation: Vendors should transparently outline their methodology for calculating ROI, including baseline comparisons, control groups (where applicable), and statistical adjustments. This allows for critical evaluation of the reported figures.
5. Alignment with Established Quality Frameworks: Solutions should demonstrate alignment with or certification by recognized quality frameworks such as NCQA, URAC, or HITRUST for data security and privacy. While not directly ROI, these ensure the foundational integrity of the platform. NCQA Digital Health Accreditation standards.

By adopting these standards, procurement teams can move beyond the “data moat” arguments that often obscure a lack of transparent outcomes, and instead focus on solutions that offer a clear, auditable path to value.

The Future: Regulatory Clarity and Revenue Durability

The healthcare AI market is maturing, and the landscape is increasingly rewarding companies that combine regulatory clarity, published outcomes, and revenue durability. This pattern is particularly visible in areas where ROI auditing is becoming a non-negotiable requirement. Companies that invest in rigorous clinical trials and health economic studies, and are willing to subject their financial claims to independent scrutiny, will ultimately gain the trust of enterprise buyers. For employers seeking to lower long-term cardiac treatment costs and health plans aiming to improve population heart health management, the message is clear: demand more than just self-reported metrics. Insist on peer-reviewed evidence and independently audited ROI. This rigorous approach is not just good procurement practice; it’s foundational to realizing the true, transformative potential of AI in value-based healthcare.